263 related articles for article (PubMed ID: 26716580)
1. Levetiracetam extended release for the treatment of patients with partial-onset seizures: A long-term, open-label follow-up study.
Chung S; Ceja H; Gawłowicz J; McShea C; Schiemann J; Lu S
Epilepsy Res; 2016 Feb; 120():7-12. PubMed ID: 26716580
[TBL] [Abstract][Full Text] [Related]
2. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial.
Peltola J; Coetzee C; Jiménez F; Litovchenko T; Ramaratnam S; Zaslavaskiy L; Lu ZS; Sykes DM;
Epilepsia; 2009 Mar; 50(3):406-14. PubMed ID: 19317886
[TBL] [Abstract][Full Text] [Related]
3. Levetiracetam extended release conversion to monotherapy for the treatment of patients with partial-onset seizures: a double-blind, randomised, multicentre, historical control study.
Chung S; Ceja H; Gawłowicz J; Avakyan G; McShea C; Schiemann J; Lu S
Epilepsy Res; 2012 Aug; 101(1-2):92-102. PubMed ID: 22516508
[TBL] [Abstract][Full Text] [Related]
4. Levetiracetam extended release and levetiracetam immediate release as adjunctive treatment for partial-onset seizures: an indirect comparison of treatment-emergent adverse events using meta-analytic techniques.
Richy FF; Banerjee S; Brabant Y; Helmers S
Epilepsy Behav; 2009 Oct; 16(2):240-5. PubMed ID: 19699156
[TBL] [Abstract][Full Text] [Related]
5. Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: open-label, noncomparative, multicenter, long-term follow-up study.
Delanty N; Jones J; Tonner F
Epilepsia; 2012 Jan; 53(1):111-9. PubMed ID: 22050371
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group.
Ben-Menachem E; Falter U
Epilepsia; 2000 Oct; 41(10):1276-83. PubMed ID: 11051122
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial.
Glauser TA; Pellock JM; Bebin EM; Fountain NB; Ritter FJ; Jensen CM; Shields WD
Epilepsia; 2002 May; 43(5):518-24. PubMed ID: 12027913
[TBL] [Abstract][Full Text] [Related]
8. Levetiracetam intravenous infusion as an alternative to oral dosing in patients with partial-onset seizures.
Baulac M; Brodie MJ; Elger CE; Krakow K; Stockis A; Meyvisch P; Falter U
Epilepsia; 2007 Mar; 48(3):589-92. PubMed ID: 17326794
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of levetiracetam (up to 2000 mg/day) in Taiwanese patients with refractory partial seizures: a multicenter, randomized, double-blind, placebo-controlled study.
Tsai JJ; Yen DJ; Hsih MS; Chen SS; Hiersemenzel R; Edrich P; Lai CW
Epilepsia; 2006 Jan; 47(1):72-81. PubMed ID: 16417534
[TBL] [Abstract][Full Text] [Related]
10. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures.
Wu XY; Hong Z; Wu X; Wu LW; Wang XF; Zhou D; Zhao ZX; Lv CZ
Epilepsia; 2009 Mar; 50(3):398-405. PubMed ID: 18657175
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety and sustained efficacy of USL255 (topiramate extended-release capsules) in patients with refractory partial-onset seizures.
Chung SS; Hogan RE; Blatt I; Lawson P B; Nguyen H; Clark AM; Anders B; Halvorsen MB;
Epilepsy Behav; 2016 Jun; 59():13-20. PubMed ID: 27084978
[TBL] [Abstract][Full Text] [Related]
12. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy.
Abou-Khalil B; Hemdal P; Privitera MD
Seizure; 2003 Apr; 12(3):141-9. PubMed ID: 12651078
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of ezogabine/retigabine as adjunctive therapy to specified single antiepileptic medications in an open-label study of adults with partial-onset seizures.
Lerche H; Daniluk J; Lotay N; DeRossett S; Edwards S; Brandt C
Seizure; 2015 Aug; 30():93-100. PubMed ID: 26216692
[TBL] [Abstract][Full Text] [Related]
14. Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group.
Maschio M; Zarabla A; Maialetti A; Fabi A; Vidiri A; Villani V; Giannarelli D
Epilepsy Behav; 2017 Aug; 73():83-89. PubMed ID: 28623754
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.
Husain A; Chung S; Faught E; Isojarvi J; McShea C; Doty P
Epilepsia; 2012 Mar; 53(3):521-8. PubMed ID: 22372628
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials.
Biton V; Gil-Nagel A; Isojarvi J; Doty P; Hebert D; Fountain NB
Epilepsy Behav; 2015 Nov; 52(Pt A):119-27. PubMed ID: 26414341
[TBL] [Abstract][Full Text] [Related]
17. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures.
Glauser TA; Ayala R; Elterman RD; Mitchell WG; Van Orman CB; Gauer LJ; Lu Z;
Neurology; 2006 Jun; 66(11):1654-60. PubMed ID: 16641323
[TBL] [Abstract][Full Text] [Related]
18. Adjunctive levetiracetam in patients aged 1 month to <4 years with partial-onset seizures: subpopulation analysis of a prospective, open-label extension study of up to 48 weeks.
Piña-Garza JE; Schiemann-Delgado J; Yang H; Duncan B; Hadac J; Hunter SJ
Clin Ther; 2010 Oct; 32(11):1935-50. PubMed ID: 21095488
[TBL] [Abstract][Full Text] [Related]
19. KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy.
Trinka E; Marson AG; Van Paesschen W; Kälviäinen R; Marovac J; Duncan B; Buyle S; Hallström Y; Hon P; Muscas GC; Newton M; Meencke HJ; Smith PE; Pohlmann-Eden B;
J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1138-47. PubMed ID: 22933814
[TBL] [Abstract][Full Text] [Related]
20. The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy.
Steinhoff BJ; Somerville ER; Van Paesschen W; Ryvlin P; Schelstraete I
Epilepsy Res; 2007 Aug; 76(1):6-14. PubMed ID: 17681453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
